Halozyme Therapeutics SEC Filings
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
110.42+0.58 (+0.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Halozyme Therapeutics filing overview
This page lists 2 recent SEC filings by Halozyme Therapeutics (HALO), including 1 4/A, 1 4. Form 10-K is the audited annual report, 10-Q the quarterly report, 8-K covers material events, and Form 4 reports insider transactions. All documents link directly to SEC EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
HALO SEC filings
| Filed | Form | Description | Document |
|---|---|---|---|
| Oct 8, 2026 | 4/A | Statement of changes in beneficial ownership (amendment) | View on EDGAR |
| Oct 8, 2026 | 4 | Statement of changes in beneficial ownership | View on EDGAR |